### [Machine Learning for PK/PD Modeling in Drug Development](https://www.certara.com/blog/machine-learning-for-pk-pd-modeling-in-drug-development/)

### [How the US FDA MIDD paired pilot program helps sponsors](https://www.certara.com/blog/how-the-us-fda-midd-paired-pilot-program-helps-sponsors/)

### [Measuring metabolites in index clinical DDI studies](https://www.certara.com/blog/measuring-metabolites-in-index-clinical-ddi-studies/)

### [Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters](https://www.certara.com/blog/why-fdas-omaveloxolone-approval-for-friedreichs-ataxia-matters/)

### [Key development considerations for cell therapies](https://www.certara.com/blog/development-considerations-cell-therapies/)

### [De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development](https://www.certara.com/blog/de-risking-drug-development-key-chemistry-manufacturing-and-controls-cmc-and-physiologically-based-pharmacokinetic-pbpk-approaches-in-early-development/)